VACC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 lapkr. 2023 @ 23:00):

Stats
Šios dienos apimtis	163 052
Vidutinė apimtis	731 881
Rinkos kapitalizacija	192.73M
EPS	$0.220 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.45
ATR14	$0.559 (17.75%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Pelletier Nadege	Buy	105 000	Share Option (Right to Buy)
2024-01-02	Griffiths Graham	Buy	96 500	Share Option (Right to Buy)
2024-01-02	Enright William	Buy	443 981	Share Option (Right to Buy)
2024-01-02	Brown Gemma	Buy	193 000	Share Option (Right to Buy)
2023-06-26	Scheeren Joseph	Buy	10 000	Ordinary Shares

INSIDER POWER
41.32
Last 95 transactions
Buy: 18 963 250 \| Sell: 20 685 755

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: 0.52 (weak)

Signal:(49.914) Neutral

Vaccitech plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVOK	0.919
PAIC	0.901
FORE	0.872
RDUS	0.87
SVAC	0.858
RMRM	0.857
SPRT	0.835
TLGT	0.834
EPZM	0.829
IVA	0.828

10 Labiausiai neigiamai susiję koreliacijos
NETE	-0.908
BOCH	-0.876
RAVN	-0.866
AMRB	-0.862
HRMY	-0.852
SBBP	-0.847
MMAC	-0.843
CFMS	-0.835
SFST	-0.829
AEPPZ	-0.827

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vaccitech plc Koreliacija - Valiuta/Žaliavos

-0.46
( neutral )

-0.21
( neutral )

-0.41
( neutral )

-0.30
( neutral )

0.53
( weak )

0.66
( moderate )

Vaccitech plc Finansinės ataskaitos

Annual	2022
Pajamos:	$44.70M
Bruto pelnas:	$2.35M (5.26 %)
EPS:	$0.140

FY	2022
Pajamos:	$44.70M
Bruto pelnas:	$2.35M (5.26 %)
EPS:	$0.140

FY	2021
Pajamos:	$268 000
Bruto pelnas:	$268 000 (100.00 %)
EPS:	$-1 067.56

FY	2020
Pajamos:	$4.82M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-371.62

Financial Reports:

No articles found.

Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.